Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $10.40, but opened at $11.29. Mesoblast shares last traded at $10.89, with a volume of 25,393 shares changing hands.
Analysts Set New Price Targets
Several research firms have commented on MESO. Cantor Fitzgerald raised shares of Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. Piper Sandler reaffirmed an "overweight" rating and issued a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Finally, Jefferies Financial Group downgraded Mesoblast from a "buy" rating to a "hold" rating in a research report on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Mesoblast currently has a consensus rating of "Moderate Buy" and an average price target of $18.00.
Check Out Our Latest Analysis on Mesoblast
Mesoblast Trading Down 2.5 %
The stock's 50 day simple moving average is $14.44 and its two-hundred day simple moving average is $13.48. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. Bank of America Corp DE increased its stake in Mesoblast by 1,503.3% during the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock worth $5,756,000 after acquiring an additional 272,595 shares during the last quarter. Oaktree Capital Management LP acquired a new stake in Mesoblast during the 4th quarter worth approximately $3,556,000. Strategic Financial Concepts LLC purchased a new position in Mesoblast in the fourth quarter valued at approximately $2,744,000. Prosperity Wealth Management Inc. lifted its position in Mesoblast by 2.0% during the fourth quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company's stock valued at $1,846,000 after buying an additional 1,795 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Mesoblast by 1,174.2% during the first quarter. GAMMA Investing LLC now owns 85,513 shares of the company's stock valued at $1,067,000 after buying an additional 78,802 shares in the last quarter. 1.43% of the stock is owned by hedge funds and other institutional investors.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
